PURPOSE: To prospectively examine quality of life (QOL) of patients with early stage breast cancer treated with accelerated partial breast irradiation (APBI) using high-dose-rate (HDR) interstitial brachytherapy. METHODS AND MATERIALS: Between March 2004 and December 2008, 151 patients with early stage breast cancer were enrolled in a phase 2 prospective clinical trial. Eligible patients included those with Tis-T2 tumors measuring ≤3 cm excised with negative surgical margins and with no nodal involvement. Patients received 3.4 Gy twice daily to a total dose of 34 Gy. QOL was measured using European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30, version 3.0, and QLQ-BR23 questionnaires. The QLQ-C30 and QLQ-BR23 questionnaires were evaluated during pretreatment and then at 6 to 8 weeks, 3 to 4 months, 6 to 8 months, and 1 and 2 years after treatment. RESULTS: The median follow-up was 55 months. Breast symptom scores remained stable in the months after treatment, and they significantly improved 6 to 8 months after treatment. Scores for emotional functioning, social functioning, and future perspective showed significant improvement 2 years after treatment. Symptomatic fat necrosis was associated with several changes in QOL, including increased pain, breast symptoms, systemic treatment side effects, dyspnea, and fatigue, as well as decreased role functioning, emotional functioning, and social functioning. CONCLUSIONS: HDR multicatheter interstitial brachytherapy was well tolerated, with no significant detrimental effect on measured QOL scales/items through 2 years of follow-up. Compared to pretreatment scores, there was improvement in breast symptoms, emotional functioning, social functioning, and future perspective 2 years after treatment.
PURPOSE: To prospectively examine quality of life (QOL) of patients with early stage breast cancer treated with accelerated partial breast irradiation (APBI) using high-dose-rate (HDR) interstitial brachytherapy. METHODS AND MATERIALS: Between March 2004 and December 2008, 151 patients with early stage breast cancer were enrolled in a phase 2 prospective clinical trial. Eligible patients included those with Tis-T2 tumors measuring ≤3 cm excised with negative surgical margins and with no nodal involvement. Patients received 3.4 Gy twice daily to a total dose of 34 Gy. QOL was measured using European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30, version 3.0, and QLQ-BR23 questionnaires. The QLQ-C30 and QLQ-BR23 questionnaires were evaluated during pretreatment and then at 6 to 8 weeks, 3 to 4 months, 6 to 8 months, and 1 and 2 years after treatment. RESULTS: The median follow-up was 55 months. Breast symptom scores remained stable in the months after treatment, and they significantly improved 6 to 8 months after treatment. Scores for emotional functioning, social functioning, and future perspective showed significant improvement 2 years after treatment. Symptomatic fat necrosis was associated with several changes in QOL, including increased pain, breast symptoms, systemic treatment side effects, dyspnea, and fatigue, as well as decreased role functioning, emotional functioning, and social functioning. CONCLUSIONS: HDR multicatheter interstitial brachytherapy was well tolerated, with no significant detrimental effect on measured QOL scales/items through 2 years of follow-up. Compared to pretreatment scores, there was improvement in breast symptoms, emotional functioning, social functioning, and future perspective 2 years after treatment.
Authors: Stephanie R Land; D Lawrence Wickerham; Joseph P Costantino; Marcie W Ritter; Victor G Vogel; Myoungkeun Lee; Eduardo R Pajon; James L Wade; Shaker Dakhil; James B Lockhart; Norman Wolmark; Patricia A Ganz Journal: JAMA Date: 2006-06-05 Impact factor: 56.272
Authors: David Cella; Lesley Fallowfield; Peter Barker; Jack Cuzick; Gershon Locker; Anthony Howell Journal: Breast Cancer Res Treat Date: 2006-06-21 Impact factor: 4.872
Authors: Katalin Lövey; János Fodor; Tibor Major; Eva Szabó; Zsolt Orosz; Zoltán Sulyok; Levente Jánváry; Georgina Fröhlich; Miklós Kásler; Csaba Polgár Journal: Int J Radiat Oncol Biol Phys Date: 2007-05-24 Impact factor: 7.038
Authors: Benjamin D Smith; Douglas W Arthur; Thomas A Buchholz; Bruce G Haffty; Carol A Hahn; Patricia H Hardenbergh; Thomas B Julian; Lawrence B Marks; Dorin A Todor; Frank A Vicini; Timothy J Whelan; Julia White; Jennifer Y Wo; Jay R Harris Journal: J Am Coll Surg Date: 2009-04-24 Impact factor: 6.113
Authors: M A Sprangers; M Groenvold; J I Arraras; J Franklin; A te Velde; M Muller; L Franzini; A Williams; H C de Haes; P Hopwood; A Cull; N K Aaronson Journal: J Clin Oncol Date: 1996-10 Impact factor: 44.544
Authors: T Wadasadawala; A Budrukkar; S Chopra; R Badwe; R Hawaldar; V Parmar; R Jalali; R Sarin Journal: Clin Oncol (R Coll Radiol) Date: 2009-09-05 Impact factor: 4.126
Authors: Electra D Paskett; Catherine M Alfano; Mario A Davidson; Barbara L Andersen; Michelle J Naughton; Aurora Sherman; Paige Green McDonald; Jennifer Hays Journal: Cancer Date: 2008-12-01 Impact factor: 6.860
Authors: Courtney M Lattimore; Max O Meneveau; Gina R Petroni; Nikole E Varhegyi; Gabriella C Squeo; Timothy N Showalter; Shayna L Showalter Journal: Brachytherapy Date: 2022-02-02 Impact factor: 2.441
Authors: Chai Hong Rim; Sung-Ja Ahn; Jin Hee Kim; Won Sup Yoon; Mison Chun; Dae Sik Yang; Jong-Hoon Lee; Kyubo Kim; Moonkyoo Kong; Suzy Kim; Juree Kim; Kyung Ran Park; Young-Joo Shin; Sun Young Ma; Bae-Kwon Jeong; Su Ssan Kim; Yong Bae Kim; Dong Soo Lee; Jaehyung Cha Journal: Health Qual Life Outcomes Date: 2017-05-10 Impact factor: 3.186
Authors: Magdalena Anna Lazarewicz; Dorota Wlodarczyk; Steinar Lundgren; Randi Johansen Reidunsdatter Journal: Qual Life Res Date: 2019-02-07 Impact factor: 4.147
Authors: Vicky Y Koh; Shaik A Buhari; Poh Wee Tan; Yun Inn Tan; Yuh Fun Leong; Arul Earnest; Johann I Tang Journal: J Contemp Brachytherapy Date: 2014-06-09
Authors: Sandra L Teichman; Sharon Do; Sharon Lum; Theodore S Teichman; William Preston; Shelly E Cochran; Carlos A Garberoglio; Roger Grove; Carol A Davis; Jerry D Slater; David A Bush Journal: Cancer Med Date: 2018-11-19 Impact factor: 4.452